The Trend for Antibiotic Use for Clostridioides (Clostridium) difficile Infection in Japan
In Japan, there is no national surveillance study of Clostridioides (Clostridium) difficile infection (CDI), and details about the epidemiology and treatment status of CDI are unknown. Additionally, clinical practice guidelines (CPGs) for CDI are published by four different institutions. All CPGs re...
Gespeichert in:
| Veröffentlicht in: | Biological & pharmaceutical bulletin 2020/04/01, Vol.43(4), pp.693-696 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 696 |
|---|---|
| container_issue | 4 |
| container_start_page | 693 |
| container_title | Biological & pharmaceutical bulletin |
| container_volume | 43 |
| creator | Ishii, Saki Muraki, Yuichi Kusama, Yoshiki Yagi, Tetsuya Goto, Ryota Ebisui, Ai Kawabe, Ayako Inose, Ryo Ohmagari, Norio |
| description | In Japan, there is no national surveillance study of Clostridioides (Clostridium) difficile infection (CDI), and details about the epidemiology and treatment status of CDI are unknown. Additionally, clinical practice guidelines (CPGs) for CDI are published by four different institutions. All CPGs recommend that the antimicrobials, vancomycin (VCM) and metronidazole (MNZ), should be selected according to disease severity. However, the trends for VCM and MNZ use in Japan remain unclear. Therefore, this study was aimed at clarifying the secular trends for VCM and MNZ use based on sales data from 2006 to 2015 and discussing its impact on CDI status and drug costs. This is the first study to clarify the antibiotic use trends for CDI treatment. We found that the total use increased over time (r = 0.0013, Pfor trend |
| doi_str_mv | 10.1248/bpb.b19-01000 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2385706126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2385706126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c702t-c9661dfb13d6403b89e2e7acbb5bb33aede8e135de7201f4a7d0e85af942c83e3</originalsourceid><addsrcrecordid>eNpdkbtvFDEQxi1ElBwhJS1aiSYUG8avfZTRCUKiSDSXhsbyY5b4tGcf9m6R_x7fXVgkmrHs-embbz4T8oHCDWWi-2L25sbQvgYKAG_IinLR1pJR-ZasoKdd3VDZXZB3OW8L0ALj5-SCM8a7ltIV-bl5xmqTMLhqiKm6DZM3Pk7eVk8Zj0_rMeYpeeejd5ir6-U-7z5Xzg-Dt37E6j4MaCcfQ-VD9aD3OrwnZ4MeM169npfk6dvXzfp7_fjj7n59-1jb4maqbd801A2GctcI4KbrkWGrrTHSGM41OuyQcumwZUAHoVsH2Ek99ILZjiO_JNcn3X2Kv2fMk9r5bHEcdcA4Z1VWlS00lDUF_fQfuo1zCsXdkRKCthIKVZ8om2LOCQe1T36n04uioA6hqxK6KqGrY-iF__iqOpsduoX-m3IB7k5A6XqrxxhGH_DfbJvbEvoYFQMGCkBwEEW7UdD0_FAaLqFj8rDA-qS0zZP-hcsoncqXjXg0JrgSh7IYXLr2WSeFgf8Bvceq8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2385441750</pqid></control><display><type>article</type><title>The Trend for Antibiotic Use for Clostridioides (Clostridium) difficile Infection in Japan</title><source>J-STAGE Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Ishii, Saki ; Muraki, Yuichi ; Kusama, Yoshiki ; Yagi, Tetsuya ; Goto, Ryota ; Ebisui, Ai ; Kawabe, Ayako ; Inose, Ryo ; Ohmagari, Norio</creator><creatorcontrib>Ishii, Saki ; Muraki, Yuichi ; Kusama, Yoshiki ; Yagi, Tetsuya ; Goto, Ryota ; Ebisui, Ai ; Kawabe, Ayako ; Inose, Ryo ; Ohmagari, Norio ; bAMR Clinical Reference Center ; Disease Control and Prevention Center ; National Center for Global Health and Medicine ; Kyoto Pharmaceutical University ; Nagoya University Graduate School of Medicine ; aDepartment of Clinical Pharmacoepidemiology ; and (cDepartment of Infectious Diseases</creatorcontrib><description>In Japan, there is no national surveillance study of Clostridioides (Clostridium) difficile infection (CDI), and details about the epidemiology and treatment status of CDI are unknown. Additionally, clinical practice guidelines (CPGs) for CDI are published by four different institutions. All CPGs recommend that the antimicrobials, vancomycin (VCM) and metronidazole (MNZ), should be selected according to disease severity. However, the trends for VCM and MNZ use in Japan remain unclear. Therefore, this study was aimed at clarifying the secular trends for VCM and MNZ use based on sales data from 2006 to 2015 and discussing its impact on CDI status and drug costs. This is the first study to clarify the antibiotic use trends for CDI treatment. We found that the total use increased over time (r = 0.0013, Pfor trend < 0.0001). While VCM use significantly decreased (r = −0.0003, Pfor trend = 0.0002), MNZ use increased (r = 0.0017, Pfor trend < 0.0001). These results show that although treatment for CDI was in line with CPGs, CDI incidence might be on an increasing trend. Additionally, despite the increased total use, the total drug costs decreased by 55% ($ 25 million) from 2006 to 2015. It was also surmised that CDI treatment in compliance with CPGs would lead to a reduction in drug costs. Hence, to understand the epidemiology of CDI, it is important to continuously investigate the use of drugs used for CDI therapy.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b19-01000</identifier><identifier>PMID: 32238711</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Antibiotics ; Antimicrobial agents ; Clostridioides difficile ; Clostridioides difficile infection ; Clostridium ; Epidemiology ; Metronidazole ; Trends ; Vancomycin</subject><ispartof>Biological and Pharmaceutical Bulletin, 2020/04/01, Vol.43(4), pp.693-696</ispartof><rights>2020 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c702t-c9661dfb13d6403b89e2e7acbb5bb33aede8e135de7201f4a7d0e85af942c83e3</citedby><cites>FETCH-LOGICAL-c702t-c9661dfb13d6403b89e2e7acbb5bb33aede8e135de7201f4a7d0e85af942c83e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32238711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishii, Saki</creatorcontrib><creatorcontrib>Muraki, Yuichi</creatorcontrib><creatorcontrib>Kusama, Yoshiki</creatorcontrib><creatorcontrib>Yagi, Tetsuya</creatorcontrib><creatorcontrib>Goto, Ryota</creatorcontrib><creatorcontrib>Ebisui, Ai</creatorcontrib><creatorcontrib>Kawabe, Ayako</creatorcontrib><creatorcontrib>Inose, Ryo</creatorcontrib><creatorcontrib>Ohmagari, Norio</creatorcontrib><creatorcontrib>bAMR Clinical Reference Center</creatorcontrib><creatorcontrib>Disease Control and Prevention Center</creatorcontrib><creatorcontrib>National Center for Global Health and Medicine</creatorcontrib><creatorcontrib>Kyoto Pharmaceutical University</creatorcontrib><creatorcontrib>Nagoya University Graduate School of Medicine</creatorcontrib><creatorcontrib>aDepartment of Clinical Pharmacoepidemiology</creatorcontrib><creatorcontrib>and (cDepartment of Infectious Diseases</creatorcontrib><title>The Trend for Antibiotic Use for Clostridioides (Clostridium) difficile Infection in Japan</title><title>Biological & pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>In Japan, there is no national surveillance study of Clostridioides (Clostridium) difficile infection (CDI), and details about the epidemiology and treatment status of CDI are unknown. Additionally, clinical practice guidelines (CPGs) for CDI are published by four different institutions. All CPGs recommend that the antimicrobials, vancomycin (VCM) and metronidazole (MNZ), should be selected according to disease severity. However, the trends for VCM and MNZ use in Japan remain unclear. Therefore, this study was aimed at clarifying the secular trends for VCM and MNZ use based on sales data from 2006 to 2015 and discussing its impact on CDI status and drug costs. This is the first study to clarify the antibiotic use trends for CDI treatment. We found that the total use increased over time (r = 0.0013, Pfor trend < 0.0001). While VCM use significantly decreased (r = −0.0003, Pfor trend = 0.0002), MNZ use increased (r = 0.0017, Pfor trend < 0.0001). These results show that although treatment for CDI was in line with CPGs, CDI incidence might be on an increasing trend. Additionally, despite the increased total use, the total drug costs decreased by 55% ($ 25 million) from 2006 to 2015. It was also surmised that CDI treatment in compliance with CPGs would lead to a reduction in drug costs. Hence, to understand the epidemiology of CDI, it is important to continuously investigate the use of drugs used for CDI therapy.</description><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Clostridioides difficile</subject><subject>Clostridioides difficile infection</subject><subject>Clostridium</subject><subject>Epidemiology</subject><subject>Metronidazole</subject><subject>Trends</subject><subject>Vancomycin</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkbtvFDEQxi1ElBwhJS1aiSYUG8avfZTRCUKiSDSXhsbyY5b4tGcf9m6R_x7fXVgkmrHs-embbz4T8oHCDWWi-2L25sbQvgYKAG_IinLR1pJR-ZasoKdd3VDZXZB3OW8L0ALj5-SCM8a7ltIV-bl5xmqTMLhqiKm6DZM3Pk7eVk8Zj0_rMeYpeeejd5ir6-U-7z5Xzg-Dt37E6j4MaCcfQ-VD9aD3OrwnZ4MeM169npfk6dvXzfp7_fjj7n59-1jb4maqbd801A2GctcI4KbrkWGrrTHSGM41OuyQcumwZUAHoVsH2Ek99ILZjiO_JNcn3X2Kv2fMk9r5bHEcdcA4Z1VWlS00lDUF_fQfuo1zCsXdkRKCthIKVZ8om2LOCQe1T36n04uioA6hqxK6KqGrY-iF__iqOpsduoX-m3IB7k5A6XqrxxhGH_DfbJvbEvoYFQMGCkBwEEW7UdD0_FAaLqFj8rDA-qS0zZP-hcsoncqXjXg0JrgSh7IYXLr2WSeFgf8Bvceq8A</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Ishii, Saki</creator><creator>Muraki, Yuichi</creator><creator>Kusama, Yoshiki</creator><creator>Yagi, Tetsuya</creator><creator>Goto, Ryota</creator><creator>Ebisui, Ai</creator><creator>Kawabe, Ayako</creator><creator>Inose, Ryo</creator><creator>Ohmagari, Norio</creator><general>The Pharmaceutical Society of Japan</general><general>Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20200401</creationdate><title>The Trend for Antibiotic Use for Clostridioides (Clostridium) difficile Infection in Japan</title><author>Ishii, Saki ; Muraki, Yuichi ; Kusama, Yoshiki ; Yagi, Tetsuya ; Goto, Ryota ; Ebisui, Ai ; Kawabe, Ayako ; Inose, Ryo ; Ohmagari, Norio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c702t-c9661dfb13d6403b89e2e7acbb5bb33aede8e135de7201f4a7d0e85af942c83e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Clostridioides difficile</topic><topic>Clostridioides difficile infection</topic><topic>Clostridium</topic><topic>Epidemiology</topic><topic>Metronidazole</topic><topic>Trends</topic><topic>Vancomycin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishii, Saki</creatorcontrib><creatorcontrib>Muraki, Yuichi</creatorcontrib><creatorcontrib>Kusama, Yoshiki</creatorcontrib><creatorcontrib>Yagi, Tetsuya</creatorcontrib><creatorcontrib>Goto, Ryota</creatorcontrib><creatorcontrib>Ebisui, Ai</creatorcontrib><creatorcontrib>Kawabe, Ayako</creatorcontrib><creatorcontrib>Inose, Ryo</creatorcontrib><creatorcontrib>Ohmagari, Norio</creatorcontrib><creatorcontrib>bAMR Clinical Reference Center</creatorcontrib><creatorcontrib>Disease Control and Prevention Center</creatorcontrib><creatorcontrib>National Center for Global Health and Medicine</creatorcontrib><creatorcontrib>Kyoto Pharmaceutical University</creatorcontrib><creatorcontrib>Nagoya University Graduate School of Medicine</creatorcontrib><creatorcontrib>aDepartment of Clinical Pharmacoepidemiology</creatorcontrib><creatorcontrib>and (cDepartment of Infectious Diseases</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishii, Saki</au><au>Muraki, Yuichi</au><au>Kusama, Yoshiki</au><au>Yagi, Tetsuya</au><au>Goto, Ryota</au><au>Ebisui, Ai</au><au>Kawabe, Ayako</au><au>Inose, Ryo</au><au>Ohmagari, Norio</au><aucorp>bAMR Clinical Reference Center</aucorp><aucorp>Disease Control and Prevention Center</aucorp><aucorp>National Center for Global Health and Medicine</aucorp><aucorp>Kyoto Pharmaceutical University</aucorp><aucorp>Nagoya University Graduate School of Medicine</aucorp><aucorp>aDepartment of Clinical Pharmacoepidemiology</aucorp><aucorp>and (cDepartment of Infectious Diseases</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Trend for Antibiotic Use for Clostridioides (Clostridium) difficile Infection in Japan</atitle><jtitle>Biological & pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>43</volume><issue>4</issue><spage>693</spage><epage>696</epage><pages>693-696</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>In Japan, there is no national surveillance study of Clostridioides (Clostridium) difficile infection (CDI), and details about the epidemiology and treatment status of CDI are unknown. Additionally, clinical practice guidelines (CPGs) for CDI are published by four different institutions. All CPGs recommend that the antimicrobials, vancomycin (VCM) and metronidazole (MNZ), should be selected according to disease severity. However, the trends for VCM and MNZ use in Japan remain unclear. Therefore, this study was aimed at clarifying the secular trends for VCM and MNZ use based on sales data from 2006 to 2015 and discussing its impact on CDI status and drug costs. This is the first study to clarify the antibiotic use trends for CDI treatment. We found that the total use increased over time (r = 0.0013, Pfor trend < 0.0001). While VCM use significantly decreased (r = −0.0003, Pfor trend = 0.0002), MNZ use increased (r = 0.0017, Pfor trend < 0.0001). These results show that although treatment for CDI was in line with CPGs, CDI incidence might be on an increasing trend. Additionally, despite the increased total use, the total drug costs decreased by 55% ($ 25 million) from 2006 to 2015. It was also surmised that CDI treatment in compliance with CPGs would lead to a reduction in drug costs. Hence, to understand the epidemiology of CDI, it is important to continuously investigate the use of drugs used for CDI therapy.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>32238711</pmid><doi>10.1248/bpb.b19-01000</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-6158 |
| ispartof | Biological and Pharmaceutical Bulletin, 2020/04/01, Vol.43(4), pp.693-696 |
| issn | 0918-6158 1347-5215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2385706126 |
| source | J-STAGE Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Antibiotics Antimicrobial agents Clostridioides difficile Clostridioides difficile infection Clostridium Epidemiology Metronidazole Trends Vancomycin |
| title | The Trend for Antibiotic Use for Clostridioides (Clostridium) difficile Infection in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A28%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Trend%20for%20Antibiotic%20Use%20for%20Clostridioides%20(Clostridium)%20difficile%20Infection%20in%20Japan&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Ishii,%20Saki&rft.aucorp=bAMR%20Clinical%20Reference%20Center&rft.date=2020-04-01&rft.volume=43&rft.issue=4&rft.spage=693&rft.epage=696&rft.pages=693-696&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b19-01000&rft_dat=%3Cproquest_cross%3E2385706126%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2385441750&rft_id=info:pmid/32238711&rfr_iscdi=true |